Table 3 prognostic factors of progression free survival
From: Oncologic and visual outcomes after postoperative proton therapy of localized conjunctival melanomas
| Bivariate analyses | Multivariate analysis | |||
|---|---|---|---|---|
| HR and 95% CI | p-value | HR and 95% CI | p-value | |
| Female (vs. Male) | 1.42 [0,70; 2.87] | 0.332 | ||
| Age | 1.01 [0.98; 1.03] | 0.574 | ||
| Pre- cancerous lesion | ||||
| nevus vs. de novo | 0.18 [0.02; 1.47] | 0.109 | ||
| PAM vs. de novo | 1.40[0.57;3.42] | 0.465 | ||
| Clinical stage | ||||
| T2 vs. T1 | 3.01 [1.04; 8.73] | 0.042 | 3.19 [1.04; 9.80] | 0.042 |
| T3 vs. T1 | 4.33 [1.88; 9.97] | 0.001 | 4.75 [1.47; 15.28] | 0.009 |
| Pathological stage | ||||
| pT2 vs. pT1 | 3.18 [1.16; 8.67] | 0.024 | ||
| pT3 vs. pT1 | 4.32 [1.82; 10.22] | 0.001 | ||
| Unifocal | 0.87 [0.38;2.02] | 0.751 | ||
| Tumor epicenter caruncle and conjunctival folds + lids vs. bulbar | 2.95[1.24;7.03] | 0.015 | ||
| Quadrangular involvement (degree) | ||||
| 90 to 180 vs. < 90 | 1.26 [0.46; 3.47] | 0.648 | ||
| > 180 vs. < 90 | 2.62 [0.75; 9.47] | 0.132 | ||
| Epithelioid type | 3.29 [1.44; 7.52] | 0.005 | 2.68 [1.12; 6.43] | 0.027 |
| Margins | ||||
| R1 vs. R0 | 0.87 [0.42; 1.80] | 0.704 | ||
| R2 vs. R0 | 0.89 [0.11; 7.03] | 0.909 | ||
| Number of mitoses> = 2 | 1.09 [0.54; 2.18] | 0.808 | ||
| Ulceration | 3.10 [1.26; 7.62] | 0.014 | ||
| Thickness > = 2 mm | 1.06 [0.46; 2.46] | 0.892 | ||
| Diameter > = 7 mm | 1.14 [0.57; 2.29] | 0.705 | ||
| Treatment | ||||
| Mitomycin | 1.10 [0.35; 3.47] | 0.875 | ||
| Cryotherapy | 0.88 [0.37; 2.11] | 0.775 | ||